Additional support

Everyone living with a cancer diagnosis could use some support along the way. These resources can help you learn more about your cancer, where to seek financial help, and how to connect with other patient support and advocacy groups.

STIVARGA^® (regorafenib) starter kit

Your STIVARGA patient starter kit components

When you start treatment with STIVARGA, you will receive a complimentary Patient Starter Kit with the following materials:

Patient Brochure

Provides an overview of what STIVARGA is, how it can help, and what to expect during treatment.

Download

STIVARGA® (regorafenib) treatment journal thumbnail

Comfort Tools

Lotion and socks for hand-foot skin reactions and a coupon for additional lotion.

Important Tips and Reminders

Download the STIVARGA Tip Sheet for information on taking and storing STIVARGA, low-fat meal options, and educational and financial support.

Download

Contact these resources if you have CRC and need additional support:

American Cancer Society (ACS)

www.cancer.org

800-227-2345

CancerCare

www.cancercare.org/diagnosis/colorectal_cancer

800-813-4673

Cancer.Net

www.cancer.net

888-651-3038

Colon Cancer Alliance

www.ccalliance.org

877-422-2030

Fight Colorectal Cancer

fightcolorectalcancer.org

877-427-2111

Contact these resources if you have GIST and need additional support:

Cancer Hope Network

www.cancerhopenetwork.org

877-467-3638

Family Caregiver Alliance

www.caregiver.org

800-445-8106

GIST Support International

www.gistsupport.org

215-340-9374

Liddy Shriver
Sarcoma Initiative

www.sarcomahelp.org

The Life Raft Group

www.liferaftgroup.org

973-837-9092

INDICATIONS

STIVARGA (regorafenib) is a prescription medicine used to treat people with:

colon or rectal cancer that has spread to other parts of the body and for which they have received previous treatment with certain chemotherapy medicines
a rare stomach, bowel, or esophagus cancer called GIST (gastrointestinal stromal tumor) that cannot be treated with surgery or that has spread to other parts of the body and for which they have received previous treatment with certain medicines
a type of liver cancer called hepatocellular carcinoma (HCC) in people who have been previously treated with sorafenib

It is not known if STIVARGA is safe and effective in children less than 18 years of age.

IMPORTANT SAFETY INFORMATION

STIVARGA (regorafenib) can cause liver problems, which can be serious and sometimes lead to death. Your healthcare provider will do blood tests to check your liver function before you start taking STIVARGA and during your treatment with STIVARGA to check for liver problems. Tell your healthcare provider right away if you experience yellowing of your skin or the white part of your eyes, nausea, vomiting, dark urine, or change in your sleep pattern.

Before taking STIVARGA, tell your healthcare provider about all of your medical conditions, including if you:

have liver problems in addition to liver cancer
have bleeding problems
have high blood pressure
have heart problems or chest pain
plan to have surgery or have had a recent surgery. You should stop taking STIVARGA at least 2 weeks before planned surgery
are pregnant or plan to become pregnant. STIVARGA can harm your unborn baby. Females and males should use effective birth control during treatment with STIVARGA and for 2 months after their last dose of STIVARGA. Tell your healthcare provider right away if you or your partner becomes pregnant either while taking STIVARGA or within 2 months after your last dose of STIVARGA
are breast-feeding or plan to breast-feed. It is not known if STIVARGA passes into your breast milk. Do not breastfeed during treatment with STIVARGA and for 2 weeks after your final dose of STIVARGA

Tell your healthcare provider about all the prescription and over-the-counter medicines, vitamins, and herbal supplements you take. Avoid drinking grapefruit juice and taking St. John’s Wort while taking STIVARGA.

STIVARGA may cause serious side effects, including:

Infection. STIVARGA may lead to a higher risk of infections especially of the urinary tract, nose, throat and lung. STIVARGA may lead to a higher risk of fungal infections of the mucous membrane, skin or the body. Tell your healthcare provider right away if you get fever, severe cough with or without an increase in mucus (sputum) production, severe sore throat, shortness of breath, burning or pain when urinating, unusual vaginal discharge or irritation, redness, swelling or pain in any part of the body
severe bleeding. STIVARGA can cause bleeding, which can be serious and sometimes lead to death. Tell your healthcare provider if you have any signs of bleeding while taking STIVARGA, including: vomiting blood or if your vomit looks like coffee grounds, pink or brown urine, red or black (looks like tar) stools, coughing up blood or blood clots, menstrual bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, bruising, and lightheadedness
a tear in your stomach or intestinal wall (bowel perforation). STIVARGA may cause a tear in your stomach or intestinal wall that can be serious and sometimes lead to death. Contact your healthcare provider immediately if you notice severe pains or swelling in your stomach area (abdomen), fever, chills, nausea, vomiting, or dehydration
a skin problem called hand-foot skin reaction and severe skin rash. Hand-foot skin reactions are common and sometimes can be severe. Tell your healthcare provider right away if you get redness, pain, blisters, bleeding, or swelling on the palms of your hands and soles of your feet, or a severe rash
high blood pressure. Your blood pressure should be checked every week for the first 6 weeks of starting STIVARGA. Your blood pressure should be checked regularly and any high blood pressure should be treated while you are receiving STIVARGA. Tell your healthcare provider if you have severe headaches, light-headedness, or changes in your vision
decreased blood flow to the heart and heart attack. Get emergency help if you have chest pain, have shortness of breath, feel dizzy, or feel like passing out
a condition called reversible posterior leukoencephalopathy syndrome (RPLS). Call your healthcare provider right away if you get severe headaches, seizure, confusion, change in vision, or problems thinking
risk of wound healing problems. Wounds may not heal properly during STIVARGA treatment. Tell your healthcare provider if you plan to have any surgery before starting or during treatment with STIVARGA.
- You should stop taking STIVARGA at least 2 weeks before planned surgery.
- Your healthcare provider should tell you when you may start taking STIVARGA again after surgery.

The most common side effects with STIVARGA include pain including stomach-area (abdomen); tiredness, weakness, fatigue; diarrhea (frequent or loose bowel movements); decreased appetite; infection; voice change or hoarseness; increase in certain liver function tests; fever; swelling, pain, and redness of the lining in your mouth, throat, stomach, and bowel (mucositis); and weight loss.

For important risk and use information about STIVARGA, please see the full Prescribing Information, including Boxed Warning.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This site is intended for US audiences only.

Last updated on March 2024